Wu, Xiaoyun
Wynne, Chris
Xu, Chenchao
Gan, Yiting
Wang, Chaohe
Thomas, Bert E.
Yu, Jin-Chen
Li, Shengfeng
Zhang, Li http://orcid.org/0000-0002-4420-2283
Funding for this research was provided by:
Bio-Thera Solutions, Ltd. (n/a)
Article History
First Online: 23 April 2019
Compliance with Ethical Standards
:
: Bio-Thera Solutions, Ltd., a biopharmaceutical company located in Guangzhou, China, provided the funding for this study.
: Xiaoyun Wu is an employee of Bio-Thera Solutions. Chris Wynne is an employee of Christchurch Clinical Studies Trust, which is the contract research organization sponsored by Bio-Thera Solutions to conduct the clinical study. Chenchao Xu is an employee of Bio-Thera Solutions. Yiting Gan is an employee of Bio-Thera Solutions. Chaohe Wang is an employee of Bio-Thera Solutions. Bert E. Thomas is an employee of Bio-Thera Solutions. Jin-Chen Yu is an employee of Bio-Thera Solutions. Shengfeng Li is an employee of Bio-Thera Solutions. Li Zhang is an employee of Bio-Thera Solutions.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study protocol was reviewed and approved by the Independent Ethics Committee (IEC), New Zealand. This phase I clinical trial was registered at ClinicalTrials.gov (identifier NCT03030430).
: Informed consent was obtained from all individual participants included in the study.